Literature DB >> 12950164

Structure and dynamics of the lantibiotic mutacin 1140.

Leif Smith1, Cherian Zachariah, Ramanan Thirumoorthy, Jim Rocca, Jan Novák, J D Hillman, Arthur S Edison.   

Abstract

Mutacin 1140 is a member of a family of ribosomally synthesized peptide bacteriocins called lantibiotics (lanthionine-containing antibiotics) and is produced by the Gram-positive bacterium Streptococcus mutans. Mutacin 1140 has been shown to be effective against a broad array of Gram-positive bacteria. Chromatography and mass spectroscopy data suggested that mutacin 1140 forms a small compact structure. Nuclear magnetic resonance (NMR) data and restrained molecular dynamics simulations showed that mutacin 1140 interconverts between multiple structures. Calculations of scalar (J) coupling constants showed the best agreement with experimental values when the entire population-weighted ensemble of structures was used, providing independent support for the ensemble. Representative structures from each major group in the ensemble had a common feature in which they are all kinked around the hinge region forming a horseshoe-like shape, and the regions of flexibility of the molecule were limited and well-defined. The structures determined in this study provide a starting point for modeling the mutacin 1140-membrane interactions and pore formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950164     DOI: 10.1021/bi034490u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries.

Authors:  Adam Pepperney; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2011-06       Impact factor: 4.609

2.  Two Flavoenzymes Catalyze the Post-Translational Generation of 5-Chlorotryptophan and 2-Aminovinyl-Cysteine during NAI-107 Biosynthesis.

Authors:  Manuel A Ortega; Dillon P Cogan; Subha Mukherjee; Neha Garg; Bo Li; Gabrielle N Thibodeaux; Sonia I Maffioli; Stefano Donadio; Margherita Sosio; Jerome Escano; Leif Smith; Satish K Nair; Wilfred A van der Donk
Journal:  ACS Chem Biol       Date:  2017-01-13       Impact factor: 5.100

3.  Biosynthesis and transport of the lantibiotic mutacin 1140 produced by Streptococcus mutans.

Authors:  Jerome Escano; Byron Stauffer; Jacob Brennan; Monica Bullock; Leif Smith
Journal:  J Bacteriol       Date:  2015-01-20       Impact factor: 3.490

4.  Site-directed mutations in the lanthipeptide mutacin 1140.

Authors:  Shaorong Chen; Shawanda Wilson-Stanford; William Cromwell; Jeffrey D Hillman; Adam Guerrero; Charlotte A Allen; Joseph A Sorg; Leif Smith
Journal:  Appl Environ Microbiol       Date:  2013-04-19       Impact factor: 4.792

Review 5.  Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.

Authors:  Leif Smith; Jd Hillman
Journal:  Curr Opin Microbiol       Date:  2008-10-24       Impact factor: 7.934

6.  Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability.

Authors:  Mengxin Geng; Leif Smith
Journal:  Appl Environ Microbiol       Date:  2018-07-17       Impact factor: 4.792

7.  The leader peptide of mutacin 1140 has distinct structural components compared to related class I lantibiotics.

Authors:  Jerome Escano; Byron Stauffer; Jacob Brennan; Monica Bullock; Leif Smith
Journal:  Microbiologyopen       Date:  2014-11-17       Impact factor: 3.139

8.  High-resolution NMR studies of antibiotics in cellular membranes.

Authors:  João Medeiros-Silva; Shehrazade Jekhmane; Alessandra Lucini Paioni; Katarzyna Gawarecka; Marc Baldus; Ewa Swiezewska; Eefjan Breukink; Markus Weingarth
Journal:  Nat Commun       Date:  2018-09-27       Impact factor: 14.919

9.  Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.

Authors:  Johan A Kers; Robert E Sharp; Anthony W Defusco; Jae H Park; Jin Xu; Mark E Pulse; William J Weiss; Martin Handfield
Journal:  Front Microbiol       Date:  2018-03-16       Impact factor: 5.640

10.  OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.

Authors:  Johan A Kers; Anthony W DeFusco; Jae H Park; Jin Xu; Mark E Pulse; William J Weiss; Martin Handfield
Journal:  PLoS One       Date:  2018-06-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.